Christina Mattina

Christina is the assistant managing editor for The American Journal of Managed Care® (AJMC®) and The American Journal of Accountable Care® (AJAC), and joined AJMC® in 2016. She oversees the entire process of the publication of the print journals, from manuscript submission to publication, and works with the editors in chief and editorial boards to promote the journals.

She has a BS in public health from Rutgers University. You can connect with Christina on LinkedIn.


Dermoscopy Holds Limited Potential to Differentiate BCC From Benign Tumors

September 24, 2022

Despite some differences in the frequency of dermoscopic features between basal cell carcinoma (BCC) and benign skin tumors, dermoscopy alone is not sufficient for a reliable diagnosis, according to a recent study.

ROSEWOOD: Zanubrutinib Combo Provides Superior Efficacy in FL

June 12, 2022

A primary analysis of the phase 2 ROSEWOOD trial finds that a combination of zanubrutinib and obinutuzumab is superior to obinutuzumab alone in relapsed/refractory follicular lymphoma (FL). Results were presented at the 2022 European Hematology Association Congress.

Late-Breaking Abstracts at EHA2022 Describe Therapy Comparisons, Investigational Treatments in Hematology

June 12, 2022

The late-breaking oral session at the 2022 European Hematology Association (EHA) Congress allowed investigators to present recently emerging data from abstracts submitted after the deadline, including outcomes from trials in chronic lymphocytic leukemia, multiple myeloma, and sickle cell disease.

AI Holds Potential to Support Ethical Principles in Hematology—but There’s a Dark Side

June 11, 2022

During a session at the 2022 European Hematology Association Congress, speakers discussed how artificial intelligence (AI) can help advance the principles of ethical medicine—but also how new technologies are being used to undermine the integrity of scientific research.

ALPINE, SEQUOIA Findings: Zanubrutinib Offers Improved HRQOL in CLL/SLL

June 11, 2022

Abstracts presented at the 2022 European Hematology Association Congress demonstrate superior health-related quality of life (HRQOL) outcomes among patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) taking zanubrutinib.

Abstracts Demonstrate Long-term, Real-world Advantages of Zanubrutinib in WM

June 10, 2022

In abstracts featured at the 2022 European Hematology Association Congress, investigators detailed long-term results of the ASPEN phase 3 trial and an expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia (WM).

EHA2022 to Offer Array of Research on Cancer Treatments, Blood Disorders

June 08, 2022

The 2022 European Hematology Association (EHA) Congress will be the group’s first hybrid meeting, in which investigators will convene both virtually and in Vienna, Austria, from June 9-12, 2022, to present cutting-edge findings in the realm of oncology and hematology.

Reversing Pandemic-Era Trends in Alcoholic Liver Disease Requires Empathetic, Multidisciplinary Care

May 24, 2022

During a State-of-the-Art Lecture at Digestive Disease Week 2022, Jessica L. Mellinger, MD, MSc, explained how the COVID-19 pandemic has driven increases in rates of alcohol use and associated liver disease, as well as what can be done at the clinic, societal, and policy levels to address these trends.